関連する実験動画
Updated: Sep 10, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
1.2K
アルツハイマー病に関連するうつ病におけるアロプレグナノロンの治療効果
Balaji Tidke1, Sakshi Itekar1, Ruchi Khobragade1
1Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra 441002, India.
Behavioural brain research
|August 25, 2025
まとめ
ニューロステロイドであるアロプレグナノロン (ALLO) は,認知能力と気分を改善することで,アルツハイマー病 (AD) とうつ病の治療に有望である. 研究によると,ALLOはADの神経炎症と神経変異を緩和する可能性がある.
科学分野:
- 神経科学
- 精神科
- 薬理学について
背景:
- アルツハイマー病 (AD) とうつ病は,神経炎症と神経ステロイド信号の障害を含む重複する神経病理学的経路を共有しています.
- ニューロステロイドであるアロプレグナノロン (ALLO) は,気分の調節,認知,神経保護に不可欠であり,GABA-A受容体と相互作用し,神経生成を促進します.
研究 の 目的:
- アルツハイマー病とうつ病の 病理的な関連を調べるため
- 病気の進行とADのうつ症状を緩和するALLOの役割を強調する.
- ADとうつ病におけるALLOのメカニズム的役割,変化したレベル,および治療の可能性をレビューする.
主な方法:
- ALLOがADモデルにおけるシナプス可塑性,アミロイド毒性,うつ病性行動に及ぼす影響を実証した臨床前研究のレビュー.
- ALLOの効果と安全性を調べた臨床試験のデータ分析
- ALLOの神経保護と抗うつ剤の評価
主要な成果:
- 臨床前データは,ALLOがシナプス可塑性を高め,ベータアミロイドの毒性を軽減し,ADモデルにおけるうつ病のような行動を緩和することを示しています.
- 臨床試験では,ADとうつ病におけるALLOの有望な治療の可能性を示唆しているが,最適化が必要である.
- ALLO値の変化は認知機能低下とADの神経精神症状と相関しています.
結論:
- ALLOは神経保護作用と抗うつ作用があり,ADによるうつ病に対する新しい治療戦略です.
- ALLOのような神経ステロイドベースの治療を統合することで,ADの認知機能と気分障害の両方に対処できます.
- ALLOの投与量,投与方法,患者の選択を最適化するために,さらなる研究が必要である.
さらに関連する動画
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.9K
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
174
関連する概念動画
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:23Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
01:21G-protein Coupled Receptors
121.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
121.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:05Long-term Depression
31.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
31.4K